These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26835885)

  • 61. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
    J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
    Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
    Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
    Tian S; Wang F; Lu S; Chen G
    Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Integrative Bioinformatics Analysis: Unraveling Variant Signatures and Single-Nucleotide Polymorphism Markers Associated with 5-FU-Based Chemotherapy Resistance in Colorectal Cancer Patients.
    Askari M; Mirzaei E; Navapour L; Karimpour M; Rejali L; Sarirchi S; Nazemalhosseini-Mojarad E; Nobili S; Cava C; Sadeghi A; Fatemi N
    J Gastrointest Cancer; 2024 Dec; 55(4):1607-1619. PubMed ID: 39240276
    [TBL] [Abstract][Full Text] [Related]  

  • 66.
    Barbirou M; Sghaier I; Bedoui S; Ben Abderrazek R; Kraiem H; Farah A; Hassiki R; Mokrani A; Mezlini A; Almawi WY; Loueslati-Yacoubi B; Bouhaouala-Zahar B
    Tumour Biol; 2020 Jun; 42(6):1010428320925237. PubMed ID: 32484056
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
    Bedoui S; Dallel M; Barbirou M; Stayoussef M; Mokrani A; Mezlini A; Bouhaouala B; Almawi WY; Yacoubi-Loueslati B
    Cancer Gene Ther; 2020 May; 27(5):311-318. PubMed ID: 31138901
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
    Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
    Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
    Park HA; Edelmann D; Canzian F; Harrison TA; Hua X; Shi Q; Silverman A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
    Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2087-2091. PubMed ID: 35984985
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
    Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer.
    Oguri T; Mitsuma A; Inada-Inoue M; Morita S; Shibata T; Shimokata T; Sugishita M; Nakayama G; Uehara K; Hasegawa Y; Ando Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):475-81. PubMed ID: 23547850
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of Nkx2-3 and TGFB1I1 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy.
    Li S; Lu X; Chi P; Pan J
    Cancer Biol Ther; 2012 Apr; 13(6):443-9. PubMed ID: 22313639
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
    Park HA; Edelmann D; Canzian F; Seibold P; Harrison TA; Hua X; Shi Q; Silverman A; Benner A; Macauda A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
    Int J Cancer; 2023 Nov; 153(9):1623-1634. PubMed ID: 37539667
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 76. Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer.
    Wu T; Cui L; Liang Z; Liu C; Liu Y; Li J
    Clin Immunol; 2013 Apr; 147(1):38-39. PubMed ID: 23501837
    [No Abstract]   [Full Text] [Related]  

  • 77. Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer.
    Li S; Xu K; Gu D; He L; Xie L; Chen Z; Fan Z; Zhu L; Du M; Chu H; Zhang Z; Wu Y; Ni M; Wang M
    J Gastroenterol; 2019 Nov; 54(11):939-949. PubMed ID: 30923916
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
    Gray V; Briggs S; Palles C; Jaeger E; Iveson T; Kerr R; Saunders MP; Paul J; Harkin A; McQueen J; Summers MG; Johnstone E; Wang H; Gatcombe L; Maughan TS; Kaplan R; Escott-Price V; Al-Tassan NA; Meyer BF; Wakil SM; Houlston RS; Cheadle JP; Tomlinson I; Church DN
    J Natl Cancer Inst; 2019 Aug; 111(8):828-836. PubMed ID: 30649440
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
    Tampellini M; Bironzo P; Di Maio M; Scagliotti GV
    Future Oncol; 2018 May; 14(12):1223-1231. PubMed ID: 29701074
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
    Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
    Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.